RxDoctor Payments Data

Richard Hamill

Infectious Disease · Houston, TXNPI 1942224795

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $136,500 of the $136,520 with a category attached, or 100.0%. Modernatx, Inc. accounts for 100.0% of it on its own, with 1 other manufacturer making up the rest. Among infectious disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$136,520in general payments, 2019–2025

Across 7 payments — averaging $19,503 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$137K
  • Merck$20
$860,989in research payments, 2019–2025

Across 50 payments — averaging $17,220 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Modernatx, Inc.$746K
  • Pfizer$115K

What the payments were for

  • Consulting fees$136,500100%
  • Education$200%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Modernatx, Inc.6$136,500
Merck1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$136,520 in reported general payments places this provider in the 95th percentile of 576 infectious disease providers in Texas.

See all infectious disease providers in Texas →

Other infectious disease in Houston

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →